Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.51 |
| ▸ | FLT1 | P17948 | 15/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308715 | 1.00 | EGFR (0.51) | EGFRFLT1KDRSYKMAOA | |
| SCHEMBL6625109 | 1.00 | EGFR (0.51) | EGFRFLT1KDRSYKMAOA | |
| SCHEMBL6623860 | 0.92 | EGFR (0.50) | EGFRFLT1KDRSYKMAOA | |
| SCHEMBL6623863 | 0.92 | EGFR (0.50) | EGFRFLT1KDRSYKMAOA | |
| SCHEMBL6624067 | 0.92 | EGFR (0.51) | EGFRFLT1KDRSYKMAOA | |
| SCHEMBL6304404 | 0.92 | EGFR (0.49) | EGFRFLT1KDRSYKMAOA | |
| SCHEMBL6627143 | 0.92 | EGFR (0.51) | EGFRFLT1KDRSYKMAOA | |
| SCHEMBL6624068 | 0.92 | EGFR (0.51) | EGFRFLT1KDRSYKMAOA | |
| SCHEMBL6302083 | 0.92 | EGFR (0.49) | EGFRFLT1KDRSYKMAOA | |
| SCHEMBL6304774 | 0.92 | EGFR (0.49) | EGFRFLT1KDRSYKMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1287001-B1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-29 | — | — | EP | disclosed |